Giulio Francolini, MD, University of Florence, Florence, Italy, shares an update on the Phase II ARTO trial (NCT03449719) investigating abiraterone acetate with or without stereotactic radiation therapy (SBRT) in patients with oligometastatic castration-resistant prostate cancer (CRPC). At six months, six versus four patients achieved a complete response and ten versus eight patients achieved a biochemical response in the with SBRT vs the without SBRT arms. Overall, abiraterone acetate plus SBRT was found to be safe, and yielded promising biochemical results. This interview took place during the 2021 Genitourinary Cancers Symposium.